Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
HRTX 
Heron Therapeuti (HRTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: HRTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.75
1 Year Target Price $4.75
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.87% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 193.15M USD | Price to earnings Ratio - | 1Y Target Price 4.75 |
Price to earnings Ratio - | 1Y Target Price 4.75 | ||
Volume (30-day avg) 3 | Beta 1.23 | 52 Weeks Range 1.04 - 2.68 | Updated Date 09/15/2025 |
52 Weeks Range 1.04 - 2.68 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.01 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -0.62% | Operating Margin (TTM) -4.4% |
Management Effectiveness
Return on Assets (TTM) 0.34% | Return on Equity (TTM) -2408.88% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 329257665 | Price to Sales(TTM) 1.29 |
Enterprise Value 329257665 | Price to Sales(TTM) 1.29 | ||
Enterprise Value to Revenue 2.2 | Enterprise Value to EBITDA 43.69 | Shares Outstanding 153292000 | Shares Floating 127762582 |
Shares Outstanding 153292000 | Shares Floating 127762582 | ||
Percent Insiders 0.74 | Percent Institutions 87.88 |
Upturn AI SWOT
Heron Therapeuti
Company Overview
History and Background
Heron Therapeutics, Inc. was founded in 1998. It is a commercial-stage biotechnology company focused on developing novel, best-in-class treatments to address unmet medical needs. The company initially focused on oncology supportive care and has expanded into acute care and pain management.
Core Business Areas
- Acute Care: Heron focuses on developing therapies to address pain management and other acute care needs. This includes non-opioid pain management solutions post-surgery.
- Oncology Supportive Care: Development and commercialization of products that address side effects of cancer treatment.
Leadership and Structure
Barry D. Quart, Pharm.D., is the Chairman and Chief Executive Officer. The company has a typical biotechnology organizational structure with departments focused on R&D, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Zynrelef: A long-acting, non-opioid local anesthetic for post-surgical pain management. Competitors include local anesthetics like bupivacaine and opioid painkillers. Market share data specific to Zynrelef is not readily and continuously updated, but revenue for 2023 was approximately $126 million.
- Aponvie: An intravenous injectable emulsion indicated for the prevention of postoperative nausea and vomiting (PONV) in adults. Revenue for 2023 was approximately $60 million. Key competitors include other antiemetics like Zofran (ondansetron) and Emend (aprepitant).
Market Dynamics
Industry Overview
The pharmaceutical industry is competitive, with companies investing heavily in R&D to develop new drugs and therapies. The pain management market is particularly active due to the opioid crisis and the need for non-addictive alternatives.
Positioning
Heron Therapeutics is positioned as an innovator in non-opioid pain management and supportive oncology care, aiming to provide safer and more effective alternatives to traditional treatments.
Total Addressable Market (TAM)
The total addressable market for post-operative pain management and PONV is estimated to be in the billions of dollars annually. Heron aims to capture a significant portion of this market through its innovative products.
Upturn SWOT Analysis
Strengths
- Innovative non-opioid pain management products
- Established commercial infrastructure
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Reliance on a limited number of key products
- Dependence on successful clinical trials and regulatory approvals
- Sales growth is lower than expected
- High debt load
Opportunities
- Expanding product portfolio through internal development or acquisitions
- Increasing market penetration of existing products
- Partnering with other companies to commercialize products
- Developing new formulations or indications for existing products
Threats
- Competition from established pharmaceutical companies
- Pricing pressures from healthcare payers
- Unfavorable regulatory changes
- Product liability claims
Competitors and Market Share
Key Competitors
- Pacira BioSciences (PCRX)
- ANI Pharmaceuticals (ANIP)
- Assertio Holdings (ASRT)
Competitive Landscape
Heron competes with established pharmaceutical companies and other biotechnology firms in the pain management and oncology supportive care markets. Heron's competitive advantages include its innovative non-opioid pain management products and its established commercial infrastructure. Disadvantages include the sales growth being lower than expected and high debt load.
Growth Trajectory and Initiatives
Historical Growth: Heron has experienced moderate revenue growth in recent years, driven by the commercialization of Zynrelef and other products.
Future Projections: Analyst estimates project continued revenue growth, driven by increased adoption of non-opioid pain management solutions. The company is expected to achieve profitability in the coming years.
Recent Initiatives: Focus on expanding the market for Zynrelef and Aponvie. Exploring new indications and formulations for existing products. Streamlining operations to reduce costs.
Summary
Heron Therapeutics is a commercial-stage biotech with innovative pain management solutions. Revenue is growing but the company needs to increase sales growth of Zynrelef and Aponvie. A significant threat is competition from established pharmaceutical companies. Heron's financial health hinges on achieving profitability and managing its debt load. The company's strategic focus on expanding its product portfolio and increasing market penetration will be crucial for future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Heron Therapeutics Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share estimates are approximate and may vary depending on the source. Future performance is not guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Heron Therapeuti
Exchange NASDAQ | Headquaters Cary, NC, United States | ||
IPO Launch date 1987-08-26 | CEO & Director Mr. Craig Alexander Collard | ||
Sector Healthcare | Industry Biotechnology | Full time employees 122 | Website https://www.herontx.com |
Full time employees 122 | Website https://www.herontx.com | ||
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.